A PHASE 1, OPEN-LABEL, SINGLE-SEQUENCE STUDY TO EVALUATE POTENTIAL DISEASE-MEDIATED DRUG-DRUG INTERACTION WITH SELECTED CYTOCHROME P450 SUBSTRATES IN ADULT SUBJECTS WITH ACTIVE OSINOPHILIC ESOPHAGITIS RECEIVING CENDAKIMAB